Assessment of FDA-approved drugs against Strongyloides ratti in vitro and in vivo to identify potentially active drugs against strongyloidiasis

被引：0
|
作者：
Jennifer Keiser
Cécile Häberli
机构：
[1] Swiss Tropical and Public Health Institute,Department of Medical Parasitology and Infection Biology
[2] University of Basel,undefined
来源：
Parasites & Vectors | / 14卷
关键词：
FDA library; Drug discovery; In vitro; In vivo;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Identification and Assessment of FDA-Approved Drugs for Repurposing as Single and Combination Therapies Against SARS-CoV-2 Infection
    Pacl, H. T.
    Tipper, J. L.
    Holder, G. D.
    Sevalkar, R. R.
    Nadeem, S.
    Chinta, K. C.
    Crouse, A.
    Steyn, A. J. C.
    Might, M.
    Harrod, K. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [22] In Vitro Screening of a 1280 FDA-Approved Drugs Library against Multidrug-Resistant and Extensively Drug-Resistant Bacteria
    Peyclit, Lucie
    Baron, Sophie Alexandra
    Hadjadj, Linda
    Rolain, Jean-Marc
    ANTIBIOTICS-BASEL, 2022, 11 (03):
  • [23] Computational screening of FDA-approved drugs to identify potential TgDHFR, TgPRS, and TgCDPK1 proteins inhibitors against Toxoplasma gondii
    Gharibi, Zahra
    Shahbazi, Behzad
    Gouklani, Hamed
    Nassira, Hoda
    Rezaei, Zahra
    Ahmadi, Khadijeh
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [24] Computational screening of FDA-approved drugs to identify potential TgDHFR, TgPRS, and TgCDPK1 proteins inhibitors against Toxoplasma gondii
    Zahra Gharibi
    Behzad Shahbazi
    Hamed Gouklani
    Hoda Nassira
    Zahra Rezaei
    Khadijeh Ahmadi
    Scientific Reports, 13
  • [25] Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
    Akinlalu, Alfred Olaoluwa
    Chamundi, Annapoorna
    Yakumbur, Donald Terseer
    Afolayan, Funmilayo I. Deborah
    Duru, Ijeoma Akunna
    Arowosegbe, Michael Aderibigbe
    Enejoh, Ojochenemi Aladi
    SCIENTIFIC AFRICAN, 2021, 13
  • [26] Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
    Risner, Kenneth
    Ahmed, Aslaa
    Bakovic, Allison
    Kortchak, Stephanie
    Bhalla, Nishank
    Narayanan, Aarthi
    VIRUSES-BASEL, 2019, 11 (12):
  • [27] Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
    De Vita, Simona
    Chini, Maria Giovanna
    Lauro, Gianluigi
    Bifulco, Giuseppe
    RSC ADVANCES, 2020, 10 (67) : 40867 - 40875
  • [28] Repurposing of FDA-Approved drugs to predict new inhibitors against key regulatory genes in Mycobacterium Tuberculosis
    Yang, Xinjun
    Alam, Aftab
    Iqbal, Naiyar
    Raza, Khalid
    BIOCELL, 2021, 45 (06) : 1569 - 1583
  • [29] Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
    Jeon, Sangeun
    Ko, Meehyun
    Lee, Jihye
    Choi, Inhee
    Byun, Soo Young
    Park, Soonju
    Shum, David
    Kim, Seungtaek
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
  • [30] Promising FDA-approved drugs with efflux pump inhibitory activities against clinical isolates of Staphylococcus aureus
    Abdel-Karim, Safaa Abdel-Aal Mohamed
    El-Ganiny, Amira Mohamed Ali
    El-Sayed, Mona Abdelmonem
    Abbas, Hisham Abdelmonem Abdelhamid
    PLOS ONE, 2022, 17 (07):
12345